California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
NEW YORK, July 17, 2017 -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and other regenerative medicines, today announced that scientists have validated a molecular mechanism that regulates scar formation in the heart, a common manifestation of aging and nearly every form of heart disease. Additionally, scientist confirmed that a protein called bone morphogenetic protein 7 (BMP-7) can prevent the generation of fibrotic signals by cardiomyocytes and may be able to serve as a therapy for cardiac fibrosis. The data was published in the journal Circulation.
Tissue fibrosis is the leading cause of organ failure. There is a lack of effective therapies. Currently, the only cure for cardiac fibrosis is heart transplantation.
“This work validates that the use of BMP-7 as a unique therapeutic strategy to prevent cardiac fibrosis,” said Joseph Hernandez, Ember’s Executive Chairman. “Ember has an extensive patent portfolio of over 400 patents in the use of BMP-7 in fibrosis and other indications. We are delighted with this data and look forward to partnering our intellectual property in this area of severe clinical need,” added Mr. Hernandez.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has several commercial products and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com
Ember Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Ember Therapeutics’ business and Ember Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact Information: Betty Rose (investors) [email protected]
